Vimarsana
Biggest News Aggregation in the World

Bayer Diagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bayer Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bayer Diagnostics Today - Breaking & Trending Today

Masimo : Announces New Member of the Board of Directors - Form 8-K -November 07, 2023 at 04:48 pm EST - Vimarsana News

Masimo : Announces New Member of the Board of Directors - Form 8-K -November 07, 2023 at 04:48 pm EST

Masimo Announces New Member of the Board of Directors Rolf A. Classon Joins Masimo's Board of Directors IRVINE, Calif - November 7, 2023 -...

Spiritus Mundi's Kon Gryllakis on the opportunities across the Asian region (LON:SPMU) - Vimarsana News

Spiritus Mundi's Kon Gryllakis on the opportunities across the Asian region (LON:SPMU)

Spiritus Mundi's Kon Gryllakis on the opportunities across the Asian region (LON:SPMU)

Accelerate Diagnostics announces appointment of Hany Massarany to Chairman of Board of Directors - Vimarsana News

Accelerate Diagnostics announces appointment of Hany Massarany to Chairman of Board of Directors

/PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) a disruptor in bloodstream infection identification and susceptibility testing today announced the...

Covalon Announces New Senior Vice President of Marketing - Vimarsana News

Covalon Announces New Senior Vice President of Marketing

/PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced...

Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study - Vimarsana News

Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study

Göran Walldius and colleagues investigate the long-term risk of a major cardiovascular event by apoB, apoA-1 and apoB/apoA-1 ratio in the Swedish AMORIS cohort.

Source: plos.org